The domestic selling price of vorasidenib-VORANIGO and the price difference with the imported version

Vorasidenib (trade name VORANIGO) is an oral small molecule inhibitor that mainly targets IDH1/2 mutant glioma. It has not yet been approved for marketing in China, so domestic hospitals and pharmacies cannot purchase original drugs or generic drugs through formal channels. At the same time, the drug has not been included in China's medical insurance list, which means that if domestic patients need medicine, they can only obtain it through overseas drug purchase. Since it has not yet entered the Chinese market, there is no official domestic pricing.

In overseas markets, the US version of the original drug of Voxanib is launched by American Servier company, with a specification of 40mg*30 tablets. According to information from public channels in the market, the price of a box of medicine may be as high as more than 380,000 yuan. It should be noted that this price will be adjusted with the fluctuation of international exchange rates, so there may be some differences in the price when patients actually purchase the drug. Such high pricing puts most patients under heavy financial pressure when taking medications.

In addition to the original version of the drug, some generic drugs have also appeared in overseas markets. Common ones include products of the same specification produced by Lucius Pharmaceuticals of Laos . The main ingredients of this generic drug remain basically the same as the original drug, and the specifications are also 40mg*30 tablets, but the price is significantly lower, about more than 7,000 yuan per box, which will also change due to exchange rate fluctuations. The price advantage of generic drugs is significant, providing another option for patients with limited financial conditions.

Generally speaking, the pricing of voroxiranib in the global market shows the characteristics of the price of original drugs is extremely high and the price of generic drugs is relatively affordable . At present, if domestic patients have needs, they will often consider purchasing through formal overseas channels. However, when choosing, they should pay attention to the authenticity of the drugs and the qualifications of the suppliers to avoid affecting the safety of treatment by purchasing substandard drugs. If voxanib can be approved for marketing in China and included in medical insurance in the future, it is expected to significantly improve patient accessibility and economic burden.

Reference link:https://www.drugs.com